Literature DB >> 17641508

Helical tomotherapy: image guidance and adaptive dose guidance.

Wolfgang A Tomé1, Hazim A Jaradat, Ian A Nelson, Mark A Ritter, Minesh P Mehta.   

Abstract

Helical tomotherapy is a volumetric image-guided, fully dynamic, intensity-modulated radiation therapy (IMRT) delivery system. The daily use of its pretreatment megavoltage (MV) CT imaging for patient setup verification allows one to correct for interfraction setup error. This is a primary requirement for the accurate delivery of complex IMRT treatment plans, which give differential radiation doses to various target volumes while conformally avoiding normal critical structures. In particular, image guidance using MV CT allows for direct target position verification with the patient in the actual treatment position just prior to therapy delivery. Moreover, since helical MV CT imaging is a slow CT imaging technique, it allows for the encoding of target motion in the resulting MV CT data set, and therefore the pretreatment verification of a motion envelope defined from four-dimensional CT.

Entities:  

Mesh:

Year:  2007        PMID: 17641508     DOI: 10.1159/000106034

Source DB:  PubMed          Journal:  Front Radiat Ther Oncol        ISSN: 0071-9676


  9 in total

1.  On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration.

Authors:  Jialu Yu; Nicholas Hardcastle; Kyoungkeun Jeong; Edward T Bender; Mark A Ritter; Wolfgang A Tomé
Journal:  Technol Cancer Res Treat       Date:  2014-11-11

2.  A survey of image-guided radiation therapy use in the United States.

Authors:  Daniel R Simpson; Joshua D Lawson; Sameer K Nath; Brent S Rose; Arno J Mundt; Loren K Mell
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

3.  High-performance GPU-based rendering for real-time, rigid 2D/3D-image registration and motion prediction in radiation oncology.

Authors:  Jakob Spoerk; Christelle Gendrin; Christoph Weber; Michael Figl; Supriyanto Ardjo Pawiro; Hugo Furtado; Daniella Fabri; Christoph Bloch; Helmar Bergmann; Eduard Gröller; Wolfgang Birkfellner
Journal:  Z Med Phys       Date:  2011-07-22       Impact factor: 4.820

4.  Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trial.

Authors:  Vasileios Askoxylakis; Alexandra D Jensen; Matthias F Häfner; Leonie Fetzner; Florian Sterzing; Joerg Heil; Christof Sohn; Johannes Hüsing; Uta Tiefenbacher; Frederik Wenz; Jürgen Debus; Holger Hof
Journal:  BMC Cancer       Date:  2011-06-15       Impact factor: 4.430

5.  The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography.

Authors:  Wei-Hsien Hou; Chun-Wei Wang; Chiao-Ling Tsai; Feng-Ming Hsu; Jason Chia-Hsien Cheng
Journal:  Radiol Oncol       Date:  2016-09-08       Impact factor: 2.991

6.  Recent advances in image-guided radiotherapy for head and neck carcinoma.

Authors:  Sameer K Nath; Daniel R Simpson; Brent S Rose; Ajay P Sandhu
Journal:  J Oncol       Date:  2009-07-29       Impact factor: 4.375

7.  Impact of the Intra- and Inter-observer Variability in the Delineation of Parotid Glands on the Dose Calculation During Head and Neck Helical Tomotherapy.

Authors:  T Piotrowski; K Gintowt; A Jodda; A Ryczkowski; W Bandyk; B Ba K; M Adamczyk; M Skorska; J Kazmierska; J Malicki
Journal:  Technol Cancer Res Treat       Date:  2015-08

8.  Prostate positioning errors associated with two automatic registration based image guidance strategies.

Authors:  D Ryan; C Rivest; Terence A Riauka; Albert D Murtha; B Gino Fallone
Journal:  J Appl Clin Med Phys       Date:  2009-10-15       Impact factor: 2.102

9.  Recommendations of megavoltage computed tomography settings for the implementation of adaptive radiotherapy on helical tomotherapy units.

Authors:  Christian Velten; Robert Boyd; Kyoungkeun Jeong; Madhur K Garg; Wolfgang A Tomé
Journal:  J Appl Clin Med Phys       Date:  2020-03-26       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.